Cmed Presents New Generation Technology to Speed and Streamline Clinical Trials at Dpharm Europe
Cmed, an innovative technology-led CRO, today announced its participation at Dpharm Europe: Disruptive Innovations to Advance Clinical Trials (8-9 February 2017, London), where it will showcase its cloud-based, new generation clinical data suite, encapsia™. Graham Belgrave, Chief Operations Officer at Cmed, will introduce encapsia™ in the “Innovative Sources & Solutions: Quickfire Disruptors” session on Wednesday 8 February between 4:30pm and 5:00pm, and highlight how a truly flexible, new seamless approach can simplify and streamline clinical trials.
Available now, encapsia™ heralds a new era for clinical trials by providing a much needed solution to the ever-rising complexity and cost of clinical research. With new and better options to collect, query, clean, visualize and analyze clinical data in real time, all within one clinical data suite, encapsia™ allows Cmed to significantly enhance the delivery of clinical trials – saving time and money.
Throughout the conference, Cmed will demonstrate some of the exciting capabilities of encapsia™ for increasing trial efficiency, improving timelines and reducing cost, at booth #2. encapsia™ is unlike any of the existing "last generation" systems and offers integrated, multiple ways for data capture, including mobile eSource, multi-media capture via an iPad and web eDC via a very modern, fast user interface. Powerful, configurable visualizations give live actionable insights and immediate analytics of a trial, allowing issues and trends to be identified and analyzed easily and rapidly.
Attendees will also be able to find out about Cmed’s full suite of services, which ranges from full-service to stand-alone solutions and functional services, such as biometrics, as well as learn about the company’s significant experience in bringing innovation to the design and conduct of complex and demanding clinical trials.
To schedule a meeting with the Cmed team during Dpharm Europe, contact Louise Holliday, Director of Business Development, at firstname.lastname@example.org.
Cmed is an innovative, full service technology-led CRO. Cmed brings together experienced people and technology, providing customers with a friendly, proactive service, and delivers this service using advanced clinical data capture, management and reporting software and processes. Cmed’s new generation clinical data suite, encapsia™, streamlines the capture, management and reporting of clinical data, saving customers time and money. Clinical data can be captured flexibly by eSource, multi-media and web eDC, while being displayed in live visual insights, providing live analytics, and allowing within suite audit trailed actions. It is fully compliant with regulatory guidelines, and allows integration with existing systems. For more information visit www.cmedresearch.com.
Cmed Clinical Services
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Rimini Street Expands Investment and Operations in Europe18.10.2017 22:00 | Pressemelding
Rimini Street, Inc., (Nasdaq: RMNI), a global provider of enterprise software products and services, and the leading third-party support provider for Oracle and SAP software products, today announced the appointment of industry leader Marc Chesover as general manager of Europe, the Middle East and Africa (EMEA). The Company also announced the launch of its French subsidiary, hiring of new staff and opening of its new office in Paris, France. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171018006654/en/ Rimini Street Expands Investment and Operations in Europe (Photo: Business Wire) Enterprise Software Veteran Leads EMEA Operations Rimini Street’s new general manager, Marc Chesover, will lead the Company’s sales and service delivery operations across EMEA, and the next p
Kite’s Yescarta™ (Axicabtagene Ciloleucel) Becomes First CAR T Therapy Approved by the FDA for the Treatment of Adult Patients With Relapsed or Refractory Large B-Cell Lymphoma After Two or More Lines of Systemic Therapy18.10.2017 21:43 | Pressemelding
Kite, a Gilead Company, (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted regular approval to Yescarta™ (axicabtagene ciloleucel), the first chimeric antigen receptor T cell (CAR T) therapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma (PMBCL), high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma (transformed follicular lymphoma, or TFL). Yescarta is not indicated for the treatment of patients with primary central nervous system lymphoma. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171018006639/en/ CAR T therapy is a breakthrough in hematologic cancer treatment in which
IFF Launches Re-Imagine…™ Programs to Tap Unmet Consumer Opportunities, Speed Innovation18.10.2017 20:15 | Pressemelding
Regulatory News: International Flavors & Fragrances Inc. (NYSE:IFF) (Euronext Paris:IFF), a leading innovator of sensory experiences that move the world, launched their Re-Imagine programs to accelerate innovation and increase agility to capture unmet opportunities in the changing food and beverage market. Based on a combination of future trends analysis, consumer insights, and a modernized cross-category development process, the programs guide the Company’s research and development efforts to ensure an innovation pipeline that addresses evolving consumer needs and desires. “The Re-Imagine programs area tangible expression of our commitment to advance taste for our customers – and consumers,” said IFF Chairman and CEO Andreas Fibig. “It is another way in which we show how we are dedicated to being our customers’ partner of choice as we progress on our business strategy, imbu
Sparkol Launches VideoScribe 318.10.2017 13:24 | Pressemelding
Introducing VideoScribe Version 3 by Sparkol. Already used by over two million people across the world to create engaging explainer videos, Version 3 of the highly intuitive software comes packed full of new features, including: An improved user experience and slick UI - animate easier than ever before Enhanced search - find exactly the image you need in record time Intelligent image recommendations - focus your creativity on your video instead Smoother performance - maximum productivity when using the software VideoScribe customers include the world’s largest brands (HP, BBC, Sky and the University of British Columbia), businesses across every sector, leading education providers, award-winning teachers, charities, campaigners, and coun
Piraeus Bank: Agreement for the Sale of Serbian Operations18.10.2017 13:06 | Pressemelding
Piraeus Bank announces that it has entered into an agreement to sell its Serbian banking and leasing operations to Direktna Banka A.D., a local Serbian banking group that has been strongly growing its presence in the market, for a total cash consideration between €58mn up to €61mn, depending on the financial performance of the divested assets until completion of the transaction, through a combination of direct sale price and simultaneous reduction of capital in Piraeus Bank Beograd AD. The transaction is conditional upon the usual corporate and regulatory approvals, including those of the National Bank of Serbia and the Hellenic Financial Stability Fund. The transaction represents another step towards the implementation of Piraeus Bank’s Restructuring Plan commitments, as those were agreed with the Directorate General of Competition of the European Commission. The transactio
Introducing InVision Studio, The World’s Most Powerful Screen Design Tool18.10.2017 13:01 | Pressemelding
InVision, the product design platform powering the world’s best digital experiences, today introduced Studio, a powerful new tool that will change the way screen design is done. InVision Studio was created by working closely with the world’s best design teams and finding inspiration in how they create beloved digital products. The launch of Studio comes at a time when modern organizations are shaping and redefining entire markets through their focus on digital customer experience. InVision already powers the product design process of more than 3 million people at tens of thousands of companies, including eighty percent of the Fortune 100 and brands like Airbnb, Uber, HBO, Amazon, IBM, Nike, and Slack. This new product reflects a major evolution of the digital product design workflow. With Studio, InVision has developed an end-to-end platform for designing digit
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom